Warning: Creating default object from empty value in /home/B/blaaoslo/subdomener/v2/wp-content/plugins/members/includes/functions.php on line 21

Warning: Cannot modify header information - headers already sent by (output started at /home/B/blaaoslo/subdomener/v2/wp-content/plugins/members/includes/functions.php:21) in /home/B/blaaoslo/subdomener/v2/wp-includes/feed-rss2-comments.php on line 8
http://v2.blaaoslo.no/arrangementer/20110528_sivil-ulyd-l%c3%b8rdag/ Just another WordPress weblog Sun, 05 Nov 2023 04:45:15 +0000 hourly 1 http://wordpress.org/?v=3.3.1 http://v2.blaaoslo.no/arrangementer/20110528_sivil-ulyd-l%c3%b8rdag/comment-page-1/#comment-114192 hpv virus Tue, 06 Jun 2023 09:42:46 +0000 http://www.blaaoslo.no/?p=4879#comment-114192 Rituximab (a humanized anti-CD20 monoclonal antibody) is a helpful remedy for Epstein-Barr virus-associated post transplant lymphoproliferative disease (EBV-PTLD). Nonetheless, hypogammaglobulinemia is a complication associated with this remedy.1,2 Little is thought in regards to the duration and severity of rituximab-induced low serum immunoglobulin (Ig) standing. EBV-PTLD. Certainly one of three patients reported by Verschuuren et al1 died of invasive aspergillosis attributable to hypogammaglobulinemia after 7 months of rituximab therapy. Tax calculation can be finalised throughout checkout. Get time restricted or full article access on ReadCube. All costs are Web prices. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Castagnola E, Dallorso S, Faraci M et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-associated submit-transplant lymphoproliferative disease preemptive therapy. Imashuku S, Naya M, Tamura S et al. Effectiveness of rituximab for chemotherapy-resistant a number of tumoral B-LPD in a haematopoietic stem cell recipient. Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in youngsters. Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in excessive-danger patients after allogeneic stem cell transplantation. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Imashuku, S., Teramura, T., Morimoto, A. et al. Extended hypogammaglobulinemia following rituximab therapy for post transplant Epstein-Barr virus-related lymphoproliferative illness. Rituximab (a humanized anti-CD20 monoclonal antibody) is a helpful remedy for Epstein-Barr virus-associated post transplant lymphoproliferative disease (EBV-PTLD).
Nonetheless, hypogammaglobulinemia is a complication associated with this remedy.1,2 Little is
thought in regards to the duration and severity of rituximab-induced low serum immunoglobulin (Ig) standing.
EBV-PTLD. Certainly one of three patients reported
by Verschuuren et al1 died of invasive aspergillosis attributable to hypogammaglobulinemia after 7 months of rituximab therapy.
Tax calculation can be finalised throughout checkout.
Get time restricted or full article access on ReadCube.
All costs are Web prices. Verschuuren EA, Stevens SJ, van Imhoff
GW et al. Treatment of posttransplant lymphoproliferative disease
with rituximab: the remission, the relapse,
and the complication. Quartier P, Brethon B, Philippet P et
al. Treatment of childhood autoimmune haemolytic anaemia with rituximab.
Castagnola E, Dallorso S, Faraci M et al. Long-lasting hypogammaglobulinemia following
rituximab administration for Epstein-Barr virus-associated submit-transplant lymphoproliferative
disease preemptive therapy. Imashuku S, Naya M, Tamura S et al.
Effectiveness of rituximab for chemotherapy-resistant a number of tumoral B-LPD in a haematopoietic stem cell recipient.
Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal
antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in youngsters.
Esser JWJ, Niesters HGM, van der Holt B et al.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular
monitoring and preemptive rituximab in excessive-danger patients after allogeneic stem cell transplantation.
Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic
stem cell transplantation. Imashuku, S., Teramura, T., Morimoto, A.
et al. Extended hypogammaglobulinemia following rituximab therapy
for post transplant Epstein-Barr virus-related lymphoproliferative illness.

]]>